Monopar Positive Early Human Clinical Data Validating Candidate Tumor Targeting

 Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr’s tumor targeting ability in humans.

MNPR-101 is Monopar’s proprietary first-in-class humanized monoclonal antibody that targets cancers expressing the urokinase plasminogen activator receptor (uPAR). These include a majority of all triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.

https://www.globenewswire.com/news-release/2024/09/12/2945115/0/en/Monopar-Announces-Positive-Early-Human-Clinical-Data-Validating-the-Tumor-Targeting-Ability-of-MNPR-101-Zr.html